Assay Designs(TM) Announces Additions to the Leade...( ANN ARBOR Mich. Oct. 1 /- Assay D...)

ANN ARBOR, Mich., Oct. 1 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, announced two key additions to its senior leadership team:

- Michael Mullenix, PhD, has joined the company as Vice President,

Research and Development. Dr. Mullenix comes to Assay Designs from

Amgen in Thousand Oaks, CA, where he was a Principal Scientist in their

Clinical Immunology group, responsible for a team of scientists

dedicated to the development of GLP compliant immunoassays for

preclinical and clinical trials. Prior to joining Amgen, Dr. Mullenix

held a series of R&D leadership positions with Molecular Staging,

Becton Dickinson, and Strategic Diagnostics.

- Gabriella Szekely-Klepser, PhD, joined Assay Designs as Vice President,

Science and Technology. Dr. Szekely-Klepser was previously an Associate

Research Fellow at Pfizer Global R&D in Ann Arbor, where she was most

recently leader of the Translational Research Biomarker Implementation

and Biologics Bioanalytical Groups. Prior to her six years at Pfizer,

Dr. Szekely-Klepser held various R&D positions at 3M Corporation.

"We are thrilled at having Mike and Gabriella join Assay Designs," stated Dan Calvo, President and CEO. "Mike has a unique blend of assay development experience from Amgen, coupled with an extensive track record of launching innovative immunoassay kit and reagent products earlier in his career. He knows how to drive an innovative and productive R&D pipeline from concept to launch. Gabriella led the establishment and expansion of Pfizer's biomarker programs across many of its therapeutic areas. She also worked closely with several key CROs to translate and scale-up complex assays. Her experience in developing and validating biomarker assays, and her understanding of the critic
'/>"/>